BLPH NASDAQ

Bellerophon Therapeutics, Inc. is a U.S.-based clinical-stage pharmaceutical company primarily focused on developing novel therapies for various cardiopulmonary conditions. Its flagship product is INOpulse, a proprietary platform designed to deliver pulsatile nitric oxide, specifically targeting pulmonary hypertension (PH). The company is actively advancing the development of INOpulse across multiple indications: Currently, INOpulse is undergoing a Phase 3 clinical trial for pulmonary hypertension linked to fibrotic interstitial lung disease. It has successfully completed a Phase 2a trial for pulmonary hypertension tied to chronic obstructive pulmonary disease. Furthermore, a Phase 2 dose escalation stage has concluded for pulmonary hypertension associated with sarcoidosis. The company is also exploring INOpulse's potential for chronic thromboembolic pulmonary hypertension and PH stemming from high altitude sickness. Founded in 2009, the enterprise, originally known as Ikaria Development LLC, adopted the Bellerophon Therapeutics, Inc. name in January 2014. Its corporate headquarters are situated in Warren, New Jersey.